Found: 10
Select item for more details and to access through your institution.
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis.
- Published in:
- BioDrugs, 2024, v. 38, n. 6, p. 821, doi. 10.1007/s40259-024-00685-y
- By:
- Publication type:
- Article
Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review.
- Published in:
- BioDrugs, 2024, v. 38, n. 6, p. 795, doi. 10.1007/s40259-024-00684-z
- By:
- Publication type:
- Article
Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy.
- Published in:
- BioDrugs, 2024, v. 38, n. 6, p. 831, doi. 10.1007/s40259-024-00683-0
- By:
- Publication type:
- Article
Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure.
- Published in:
- BioDrugs, 2024, v. 38, n. 6, p. 727, doi. 10.1007/s40259-024-00677-y
- By:
- Publication type:
- Article
Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins.
- Published in:
- BioDrugs, 2024, v. 38, n. 6, p. 769, doi. 10.1007/s40259-024-00682-1
- By:
- Publication type:
- Article
Pulmonary Arterial Hypertension and TGF-β Superfamily Signaling: Focus on Sotatercept.
- Published in:
- BioDrugs, 2024, v. 38, n. 6, p. 743, doi. 10.1007/s40259-024-00680-3
- By:
- Publication type:
- Article
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?
- Published in:
- BioDrugs, 2024, v. 38, n. 6, p. 845, doi. 10.1007/s40259-024-00678-x
- By:
- Publication type:
- Article
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study.
- Published in:
- BioDrugs, 2024, v. 38, n. 6, p. 867, doi. 10.1007/s40259-024-00681-2
- By:
- Publication type:
- Article
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.
- Published in:
- BioDrugs, 2024, v. 38, n. 6, p. 755, doi. 10.1007/s40259-024-00671-4
- By:
- Publication type:
- Article
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects.
- Published in:
- BioDrugs, 2024, v. 38, n. 6, p. 855, doi. 10.1007/s40259-024-00679-w
- By:
- Publication type:
- Article